How to use Technology Searches
The ‘Technologies Searched’-section displays profiles of unmet needs covering a broad spectrum from scientific expertise to clinical stage product candidates. Text search allows the use of phrases not yet part of our category lists. Key words can be used in combination and help identifying the hits most relevant for you.
A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection “Biomedicine, Diagnostics” in ‘Sector’, “Cancerous, neoplasmatic” in ‘Disease Category, “Drugs, Small Molecule” in ‘Technology’ and “Preclinical” in ‘Development Stage. Selection of “Enabling Technology, Platform technology” in ‘Sector’ will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.
Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee. Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.
Summary
Optimata is seeking discontinued oncology compounds
Organization name
Optimata Ltd.
Profile
Optimata is a privately owned science-based company from Israel and develops computerized tools for navigating drug development towards better drugs faster.
Using its proprietary technology, Optimata identifies derailed drug candidates and redirects their clinical development path to market. Using bio-mathematics to develop a predictive bio-simulation software toolkit, this technology provides a comprehensive drug development solution, from the pre-clinical phase through treatment personalization. It thoroughly unfolds drug<=>patient dynamic interactions, enabling drug developers to perform rapid virtual clinical trials and to forecast optimal drug regimen<=>patient population<=>clinical indication match for a given trial end point.
They are seeking to in-license discontinued oncology compounds. The compounds sought would have passed phase I successfully and were discontinued afterwards. They prefer to focus on compounds which target the ATC/DDD drug classes L01, L03, L04.
URL
http://www.optimata.comYour Feedback
back
print this page
